AstraZeneca teams up with Ionis to develop and market eplontersen
Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Dec 21
Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)
29 Dec 21
The Drugs Controller General of India (DCGI) has also granted emergency use approval for Biological E’s Covid-19 vaccine…
28 Dec 21
Keytruda plus Lenvima combination is currently approved in Japan, the US and Europe to treat certain advanced endometrial…
27 Dec 21
Covaxin was already approved by India’s Central Drugs Standards Control Organisation (CDSCO) for restricted use in an emergency…
24 Dec 21
The US regulator’s approval is based on the Phase 3 MOVe-OUT trial, which assessed molnupiravir 800 mg twice-daily…
24 Dec 21
Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…
23 Dec 21
The US regulator’s decision is based on the data from the Phase 2/3 EPIC-HR trial, which enrolled non-hospitalised…
23 Dec 21
The acquisition will enable Novartis to add Gyroscope’s investigational gene therapy, GT005, to its portfolio
22 Dec 21
The acquisition of Amunix will enable Sanofi to discover and develop advanced T-cell engagers (TCE) and cytokine medicines…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 21
The sBLA submission was based on positive results from the Phase 3 trial, in which Ultomiris significantly improved…